This week Pfizer seeks Emergency Use Authorization for their COVID-19 oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.
Your search for psilocybin returned 6 results
Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I drug in the US.
The designation was granted to COMPASS Pathways, a life sciences company investigating psilocybin in a Phase 2b trial involving 216 patients at multiple sites across Europe and North America.
Currently, psilocybin, a serotonin receptor agonist, is classified as a Schedule I agent as it has not been approved by the Food and Drug Administration (FDA) for any therapeutic use.
A single moderate-dose of psilocybin (a hallucinogenic compound contained in psychedelic mushrooms) was found to produce enduring anxiolytic and antidepressant effects in distressed cancer patients with life-threatening diagnoses.
A single dose of psilocybin can alleviate negative moods in patients with life-threatening cancer, a new study has found.